Harnessing the apoptotic programs in cancer stem-like cells

EMBO Rep. 2015 Sep;16(9):1084-98. doi: 10.15252/embr.201439675. Epub 2015 Aug 7.

Abstract

Elimination of malignant cells is an unmet challenge for most human cancer types even with therapies targeting specific driver mutations. Therefore, a multi-pronged strategy to alter cancer cell biology on multiple levels is increasingly recognized as essential for cancer cure. One such aspect of cancer cell biology is the relative apoptosis resistance of tumor-initiating cells. Here, we provide an overview of the mechanisms affecting the apoptotic process in tumor cells emphasizing the differences in the tumor-initiating or stem-like cells of cancer. Further, we summarize efforts to exploit these differences to design therapies targeting that important cancer cell population.

Keywords: apoptosis; cancer stem cells; cancer therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Apoptosis* / genetics
  • Humans
  • Inhibitor of Apoptosis Proteins / antagonists & inhibitors
  • Inhibitor of Apoptosis Proteins / metabolism
  • Neoplasms / metabolism
  • Neoplasms / pathology*
  • Neoplasms / therapy*
  • Neoplastic Stem Cells / physiology*
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • BCL2 protein, human
  • Inhibitor of Apoptosis Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Tumor Suppressor Protein p53